Multibagger Selection: Grok 4.5's picks
Grok 4.5 picked INOD, NRIX, BBAI, IVA, CALX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 72% | — | — |
| 2 | NRIX | — | 68% | — | — |
| 3 | BBAI | — | 62% | — | — |
| 4 | IVA | — | 58% | — | — |
| 5 | CALX | — | 55% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +8.05% | +8.00% | 1.23x | 0 |
The model's market view
Small- and mid-cap equities trade at a valuation discount to large-caps amid elevated rates volatility and AI-driven dispersion. Liquidity and institutional interest remain selective, favoring companies with near-term operating inflection, verifiable contract or clinical catalysts, and balance-sheet runway sufficient to reach those events without emergency dilution.
Why each pick
INOD
Innodata is a data-engineering and AI-systems services provider whose revenue and free-cash-flow growth are accelerating on demand for model training, evaluation and proprietary datasets. Q2 2026 revenue rose 58 percent year-over-year to $92.1 million with adjusted gross margin of 49 percent and adjusted EBITDA up 92 percent, demonstrating operating leverage. Management reiterated full-year 2026 revenue growth guidance of at least 40 percent. Customer concentration is declining while new frontier-lab and hyperscaler programs are ramping. The valuation leaves room for multiple expansion if growth and margins continue.
NRIX
Nurix Therapeutics advanced its targeted protein-degradation pipeline with a transformative collaboration with Roche valued at up to $2.3 billion, including substantial upfront and milestone economics. The company has initiated a registrational Phase 3 trial of bexobrutideg in relapsed/refractory CLL/SLL and reported significant collaboration revenue that has turned near-term profitability positive on a reported basis. Cash runway is extended by the non-dilutive Roche funding, supporting multiple pipeline readouts.
BBAI
BigBear.ai is a mission-focused AI software company serving defense, intelligence and federal civilian customers. Recent announcements of more than $225 million in contract awards since July 2026, including more than 25 generative-AI awards, expand the customer base beyond prior concentration. Backlog stood near $270 million at mid-year with sequential growth. Gross-margin expansion into the low-to-mid 30 percent range and affirmative full-year 2026 revenue guidance of $135-165 million support an operating inflection narrative.
IVA
Inventiva is a clinical-stage biotech focused on lanifibranor, an oral pan-PPAR agonist in the fully enrolled Phase 3 NATiV3 trial for MASH with moderate-to-advanced fibrosis. Topline results are expected in Q4 2026. Positive data would support a potential U.S. regulatory submission in H1 2027. Cash and deposits of approximately €234 million provide runway into at least mid-2027, with conditional extensions possible on positive data.
CALX
Calix provides cloud and software platforms that enable broadband service providers to deliver managed services and subscriber experiences. Recent results show revenue growth in the low-to-mid 20 percent range, return to GAAP profitability, positive free cash flow and expanding gross margins near 55-57 percent. Share-repurchase authorization increases and product expansions into prplOS and SmartLife applications support continued operating leverage.
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 1.5 Pro | ASTS, LUNR, RXRX, ACHR, IONQ |
| Muse Spark 1.1 | EOSE, CAPR, SERV, AMPL, SOUN |
| GPT-6 | BKSY, AMPX, INOD, RDW, EOSE |
| DeepSeek | UMAC, ONDS, RCAT, INOD, MPTI |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.